1. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. (15th December 2017) Authors: Swain, S M; Ewer, M S; Viale, G; Delaloge, S; Ferrero, J -M; Verrill, M; Colomer, R; Vieira, C; Werner, T L; Douthwaite, H; Bradley, D; Waldron-Lynch, M; Kiermaier, A; Eng-Wong, J; Dang, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 646 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗